Inhibrx Biosciences, Inc. INBX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$33.44M-1.8% | -$32.83M+6.9% | -$35.26M-23.0% | -$28.65M+33.8% | -$43.31M— | ||
| $537K-4.8% | $564K-3.1% | $582K-12.1% | $662K-1.9% | $675K-2.0% | ||
| $2.65M-3.3% | $2.74M-13.6% | $3.18M+14.6% | $2.77M+13.1% | $2.45M-17.8% | ||
| $732K+14.0% | $642K+0.6% | $638K+1.9% | $626K+17.4% | $533K— | ||
| $0— | —— | -$127K— | —— | -$200K-335% | ||
| $2.82M+440% | -$829K+45.4% | -$1.52M-153% | -$600K-70.0% | -$353K— | ||
| -$10.19M-610% | -$1.43M+5.3% | -$1.52M+64.7% | -$4.3M-249% | $2.88M— | ||
| $0— | $0-100% | $22K+267% | $6K+121% | -$28K-124% | ||
| -$549K-2.6% | -$535K-2.5% | -$522K-42.2% | -$367K-115% | -$171K-144% | ||
| $9K+101% | -$706K-23,433% | -$3K-100% | $672K+3,853% | $17K+112% | ||
| -$38.03M-26.2% | -$30.12M+10.9% | -$33.82M-12.9% | -$29.95M+16.6% | -$35.9M+17.9% | ||
| $0— | —— | $10K— | —— | $21K+31.3% | ||
| $0— | —— | -$7K— | —— | -$21K-31.3% | ||
| $471K-62.4% | $1.25M+256% | $352K— | $0— | $0— | ||
| $75.46M+5,918% | $1.25M+256% | $352K— | $0-100% | $99.84M— | ||
| $37.44M+230% | -$28.87M— | —— | —— | $63.92M+246% | ||
| $2.78M+10.5% | $2.51M-1.2% | $2.54M0.0% | $2.54M+95.8% | $1.3M— | ||
| $0— | —— | —— | $2K— | $0— | ||
| $732K+14.0% | $642K+0.6% | $638K+1.9% | $626K+17.4% | $533K— | ||
| $0— | —— | —— | —— | -$23K— | ||
| -$549K-2.6% | -$535K-2.5% | -$522K-42.2% | -$367K-115% | -$171K-144% | ||
| $9K+101% | -$706K-23,433% | -$3K-100% | $672K+3,853% | $17K+112% | ||
| $1.06M+351% | -$423K-1,592% | -$25K+88.7% | -$222K+69.6% | -$730K+72.0% | ||
| —— | $450.75K0.0% | $450.75K0.0% | $450.75K0.0% | $450.75K-5.0% | ||
| $483K— | —— | $456K+2.7% | $444K+2.3% | $434K— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $0— | —— | —— | —— | $125K— | ||
| —— | $31.25K0.0% | $31.25K0.0% | $31.25K0.0% | $31.25K— | ||
| -$549K-2.6% | -$535K-2.5% | -$522K-42.2% | -$367K-115% | -$171K-144% | ||
| —— | $430K0.0% | $430K0.0% | $430K0.0% | $430K— | ||
| $1.29M— | —— | —— | —— | $1.72M— | ||
| $74.99M— | —— | —— | —— | $99.97M— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $0— | —— | —— | $2K— | $0— | ||
| -$38.03M-26.2% | -$30.12M+11.0% | -$33.83M-13.0% | -$29.95M+16.6% | -$35.92M+17.9% | ||
| -$38.03M-26.2% | -$30.12M+11.0% | -$33.83M-13.0% | -$29.95M+16.6% | -$35.92M+17.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Inhibrx Biosciences, Inc. generate?
- Inhibrx Biosciences, Inc. (INBX) generated -$131.9M in operating cash flow over the trailing twelve months.
- What is Inhibrx Biosciences, Inc.'s free cash flow?
- After $47.0K of capital expenditures, Inhibrx Biosciences, Inc.'s free cash flow was -$131.9M over the trailing twelve months, up 21.8% year over year.
- Where does Inhibrx Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
